BACKGROUND: In this study (NCT00985088) we evaluated different formulations of an H1N1 2009 pandemic influenza vaccine that deliver various viral hemagglutinin (HA) doses with or without AS03 (a tocopherol-based oil-in-water adjuvant system). METHODS: A total of 1340 healthy subjects aged ≥18 years were randomized to receive 1 or 2 doses of an adjuvanted (3.75-μg HA/AS03(A) or 1.9-μg HA/AS03(B)) or nonadjuvanted vaccine formulation. Safety and immunogenicity (by hemagglutination-inhibition [HI] assay) after each dose and 6 months after dose 1 are reported here. RESULTS: A single dose of AS03(A)-adjuvanted3.75-μg HA H1N1 2009 induced the strongest immune responses in subjects aged 18-64 years (seroprotection rate [SPR], 97.2%; seroconversion rate [SCR], 90.1%) as well as in subjects aged >64 years (SPR, 91.1%; SCR, 78.2%) 21 days after vaccination. Six months after dose 1, subjects who received 2 doses of either the adjuvanted formulation or 1 dose of the adjuvanted 3.75-μg HA formulation continued to meet all Center for Biologics Evaluation and Research and Committee for Medicinal Products for Human Use criteria. All formulations had clinically acceptable safety profiles. CONCLUSION: A single dose of the 3.75-μg HAAS03(A)-adjuvanted H1N1 2009 influenza vaccine was highly immunogenic in both age strata (18-64 and >64 years), inducing long-term persistence of the immune response until at least 6 months after dose 1.
RCT Entities:
BACKGROUND: In this study (NCT00985088) we evaluated different formulations of an H1N1 2009 pandemic influenza vaccine that deliver various viral hemagglutinin (HA) doses with or without AS03 (a tocopherol-based oil-in-water adjuvant system). METHODS: A total of 1340 healthy subjects aged ≥18 years were randomized to receive 1 or 2 doses of an adjuvanted (3.75-μg HA/AS03(A) or 1.9-μg HA/AS03(B)) or nonadjuvanted vaccine formulation. Safety and immunogenicity (by hemagglutination-inhibition [HI] assay) after each dose and 6 months after dose 1 are reported here. RESULTS: A single dose of AS03(A)-adjuvanted 3.75-μg HA H1N1 2009 induced the strongest immune responses in subjects aged 18-64 years (seroprotection rate [SPR], 97.2%; seroconversion rate [SCR], 90.1%) as well as in subjects aged >64 years (SPR, 91.1%; SCR, 78.2%) 21 days after vaccination. Six months after dose 1, subjects who received 2 doses of either the adjuvanted formulation or 1 dose of the adjuvanted 3.75-μg HA formulation continued to meet all Center for Biologics Evaluation and Research and Committee for Medicinal Products for Human Use criteria. All formulations had clinically acceptable safety profiles. CONCLUSION: A single dose of the 3.75-μg HA AS03(A)-adjuvanted H1N1 2009 influenza vaccine was highly immunogenic in both age strata (18-64 and >64 years), inducing long-term persistence of the immune response until at least 6 months after dose 1.
Authors: Joon Young Song; Hee Jin Cheong; Yu Bin Seo; In Seon Kim; Ji Yun Noh; Jung Yeon Heo; Won Suk Choi; Jacob Lee; Woo Joo Kim Journal: Clin Vaccine Immunol Date: 2012-02-29
Authors: Larry R Smith; Walter Wodal; Brian A Crowe; Astrid Kerschbaum; Peter Bruehl; Michael G Schwendinger; Helga Savidis-Dacho; Sean M Sullivan; Mark Shlapobersky; Jukka Hartikka; Alain Rolland; P Noel Barrett; Otfried Kistner Journal: Hum Vaccin Immunother Date: 2013-03-06 Impact factor: 3.452
Authors: Adrian J Reber; Jin Hyang Kim; Laura A Coleman; Sarah M Spencer; Jessie R Chung; Jufu Chen; Paul Gargiullo; Maria E Sundaram; Edward A Belongia; David K Shay; Jacqueline M Katz; Suryaprakash Sambhara Journal: J Infect Dis Date: 2016-08-28 Impact factor: 5.226
Authors: Anna J X Zhang; Can Li; Kelvin K W To; Hou-Shun Zhu; Andrew C Y Lee; Chuan-Gen Li; Jasper F W Chan; Ivan F N Hung; Kwok-Yung Yuen Journal: Clin Vaccine Immunol Date: 2014-02-12
Authors: Grace Ledet; Sarala Pamujula; Valencia Walker; Shana Simon; Richard Graves; Tarun K Mandal Journal: Drug Dev Ind Pharm Date: 2013-04-19 Impact factor: 3.225